Medicines Pool includes Chinese firm in new sub-licenses
This article was originally published in Scrip
Executive Summary
The Medicines Patent Pool (MPP) has announced seven new sub-licensing pacts including the first one with a Chinese firm, for the manufacture of the generic HIV medicines atazanavir ( Bristol-Myers Squibb's Reyataz) and dolutegravir (ViiV Healthcare's Tivicay).